Day One Ownership
| DAWN Stock | USD 8.28 0.03 0.36% |
Shares in Circulation | First Issued 2020-03-31 | Previous Quarter 96.9 M | Current Value 93.6 M | Avarage Shares Outstanding 63.9 M | Quarterly Volatility 21.1 M |
Day |
Day Stock Ownership Analysis
About 17.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.68. Some equities with similar Price to Book (P/B) outperform the market in the long run. Day One Biopharmaceu recorded a loss per share of 1.02. The entity had not issued any dividends in recent years. Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. Day One operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 94 people. To learn more about Day One Biopharmaceuticals call Jeremy MBA at 650 484 0899 or check out https://dayonebio.com.Day Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Day One is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Day One Biopharmaceuticals backward and forwards among themselves. Day One's institutional investor refers to the entity that pools money to purchase Day One's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Alyeska Investment Group, L.p. | 2024-12-31 | 2.5 M | Timessquare Capital Management, Llc | 2024-12-31 | 1.7 M | T. Rowe Price Associates, Inc. | 2024-12-31 | 1.7 M | Geode Capital Management, Llc | 2024-12-31 | 1.5 M | Vestal Point Capital Lp | 2024-12-31 | 1.4 M | Hhg Plc | 2024-12-31 | 1.3 M | Boxer Capital Management, Llc | 2024-12-31 | 1.2 M | Boxer Capital Llc | 2024-09-30 | 1.2 M | Marshall Wace Asset Management Ltd | 2024-12-31 | 1.1 M | Fmr Inc | 2024-12-31 | 12.9 M | Blackrock Inc | 2024-12-31 | 6.2 M |
Day One Biopharmaceu Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Day One insiders, such as employees or executives, is commonly permitted as long as it does not rely on Day One's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Day One insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Day One Outstanding Bonds
Day One issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Day One Biopharmaceu uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Day bonds can be classified according to their maturity, which is the date when Day One Biopharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Day One Corporate Filings
10K | 6th of March 2025 An amendment to a previously filed Form 10-K | ViewVerify |
F3 | 28th of February 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 25th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 21st of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Pair Trading with Day One
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Day One position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Day One will appreciate offsetting losses from the drop in the long position's value.Moving together with Day Stock
Moving against Day Stock
| 0.68 | LUCD | Lucid Diagnostics | PairCorr |
| 0.61 | WM | Waste Management | PairCorr |
| 0.45 | PG | Procter Gamble | PairCorr |
| 0.4 | GE | GE Aerospace | PairCorr |
The ability to find closely correlated positions to Day One could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Day One when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Day One - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Day One Biopharmaceuticals to buy it.
The correlation of Day One is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Day One moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Day One Biopharmaceu moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Day One can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Day One Biopharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Day One. If investors know Day will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Day One listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Day One Biopharmaceu is measured differently than its book value, which is the value of Day that is recorded on the company's balance sheet. Investors also form their own opinion of Day One's value that differs from its market value or its book value, called intrinsic value, which is Day One's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Day One's market value can be influenced by many factors that don't directly affect Day One's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Day One's value and its price as these two are different measures arrived at by different means. Investors typically determine if Day One is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Day One's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.